Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
Washington University School of Medicine
St. Jude Children's Research Hospital
City of Hope Medical Center
Roswell Park Cancer Institute
Ohio State University Comprehensive Cancer Center
University College, London
Fred Hutchinson Cancer Center
Washington University School of Medicine
M.D. Anderson Cancer Center
Washington University School of Medicine
Washington University School of Medicine
Hebei Senlang Biotechnology Inc., Ltd.
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of Washington
Washington University School of Medicine
H. Lee Moffitt Cancer Center and Research Institute
Polyphor Ltd.
Imperial College London